Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease

Nephrology Dialysis Transplantation

Volumn 28, Issue 2, 2013, Pages 380-385

  Helal, Imed ^a   McFann, Kim ^b   Reed, Berenice ^a   Yan, Xiang Dong ^a   Schrier, Robert W ^a   Fick Brosnahan, Godela M ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Food Science and Human Nutrition   (United States)

Author keywords

autosomal dominant polycystic kidney disease; end stage renal disease; hypertension; kidney volume; uric acid

Indexed keywords

ALLOPURINOL; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; URIC ACID;

ADULT; ARTICLE; BODY MASS; CREATININE CLEARANCE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY BLOOD FLOW; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; KIDNEY VOLUME; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; RENAL SYSTEM PARAMETERS; RETROSPECTIVE STUDY; UNITED STATES; URIC ACID BLOOD LEVEL;

ADULT; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION; HYPERURICEMIA; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; ORGAN SIZE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; URIC ACID;

EID: 84874575829     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs417     Document Type: Article

References (51)

1. Iglesias CG, Torres VE, Offord KP et al. Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935-1980. Am J Kidney Dis 1983; 2: 630-639 (Pubitemid 13078640)
2. Ecder T, Fick-Brosnahan GM, Schrier RW. Polycystic kidney disease. In: Schrier RW (ed). Diseases of the Kidney and Urinary Tract. 8th edn. Philadelphia: Lippincott Williams & Wilkins, 2007, 502-539
3. Johnson AM, Gabow PA. Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol 1997; 8: 1560-1567 (Pubitemid 27496474)
4. Torres VE, Grantham JJ, Chapman AB et al. Potentially modifiable factors affecting the progression of with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6: 640-647
5. Wang D, Iversen J, Wilcox CS et al. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal dominant polycystic kidney disease. Kidney Int 2003; 64: 1381-1388 (Pubitemid 37153804)
6. Torres VE, King BF, Chapman AB et al. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2007; 2: 112-120
7. Meijer E, Rook M, Tent H et al. Early renal abnormalities in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2010; 5: 1091-1098
8. Chapman AB, Johnson AM, Rainguet S et al. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1997; 8: 1292-1297 (Pubitemid 27493634)
9. Fick GM, Johnson AM, Hammond WS et al. Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995; 5: 2048-2056
10. Orskov B, Sorensen VR, Feldt-Rasmussen B et al. Changes in causes of death and risk of cancer in Danish patients with autosomal dominant polycystic kidney disease and end-stage renal disease. Nephrol Dial Transplant 2012; 27: 1607-1613
11. Loeffler LF, Navas-Acien A, Brady TM et al. Uric acid level and elevated blood pressure in US adolescents: National Health and Nutrition Examination Survey, 1999-2006. Hypertension 2012; 59: 811-817
12. Krishnan E, Kwoh CK, Schumacher HR et al. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007; 49: 298-303 (Pubitemid 46143005)
13. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821
14. Khosla UM, Zharikov S, Finch JL et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67: 1739-1742 (Pubitemid 40577708)
15. Weiner DE, Tighiouart H, Elsayed EF et al. Uric acid and incident kidney disease in the community. J Am Soc Nephrol 2008; 19: 1204-1211
16. Bellomo G, Venanzi S, Verdura C et al. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis 2010; 56: 264-272
17. Mok Y, Lee SJ, Kim MS et al. Serum uric acid and chronic kidney disease: the Severance cohort study. Nephrol Dial Transplant 2012; 27: 1831-1835
18. Chonchol M, Shlipak MG, Katz R et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007; 50: 239-247 (Pubitemid 47095076)
19. Mazzali M, Hughes J, Kim YG et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101-1106 (Pubitemid 34252813)
20. Chapman AB, Johnson A, Gabow PA et al. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990; 323: 1091-1096 (Pubitemid 20370729)
21. Loghman-Adham M, Soto CE, Inagami T et al. The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol 2004; 287: F775-F788 (Pubitemid 39280514)
22. Lee YH, Song GG. Pathway analysis of genome-wide association studies on uric acid concentrations. Hum Immunol 2012; http://dx. doi.org/10.1016/j.humimm. 2012.05.004
23. Ravine D, Gibson RN, Walker RG et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 1994; 343: 824-827 (Pubitemid 24147512)
24. Fick-Brosnahan GM, Belz MM, McFann KK et al. Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study. Am J Kidney Dis 2002; 39: 1127-1134 (Pubitemid 34591926)
25. Tein JY, MacKinnon DP. Estimating mediated effects with survival data. In: Yanai H, Rikkyo AO, Shigemasu K et al. (eds). New Developments on Psychometrics. Tokyo, Japan: Springer Verlag Tokyo Inc., 2003, 405-412
26. MacKinnon DP, Lockwood CM, Hoffman JM et al. A comparison of methods to test mediation and other intervening variable effects. Psychol Methods 2002; 7: 83-104
27. Corry DB, Eslami P, Yamamoto K et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008; 26: 269-275
28. Yu MA, Sanchez-Lozada LG, Johnson RJ et al. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 2010; 28: 1234-1242
29. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension. JAMA 2008; 300: 924-932
30. King BF, Torres VE, Brummer ME et al. Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP). Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease. Kidney Int 2003; 64: 2214-2221 (Pubitemid 37449557)
31. Schrier RW, De Wardener HE. Tubular reabsorption of sodium ion: influence of factors other than aldosterone and glomerular filtration rate. 1. N Engl J Med 1971; 285: 1231-1243
32. Schrier RW, De Wardener HE. Tubular reabsorption of sodium ion: influence of factors other than aldosterone and glomerular filtration rate. 2. N Engl J Med 1971; 285: 1292-1303
33. Farquharson CA, Butler R, Hill A et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106: 221-226 (Pubitemid 34761303)
34. Butler R, Morris AD, Belch JJ et al. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000; 35: 746-751 (Pubitemid 30165320)
35. Kao MP, Ang DS, Gandy SJ et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 2011; 22: 1382-1389
36. Kanbay M, Huddam B, Azak A et al. A randomized study of allopurinol on endothelial function and estimated glomerular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 2011; 6: 1887-1894
37. Wang D, Strandgaard S, Borresen ML et al. Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease. Am J Kidney Dis 2008; 51: 184-191
38. Chapman AB, Stepniakowski K, Rahbari-Oskoui F. Hypertension in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 2010; 17: 153-163
39. Turkmen K, Oflaz H, Uslu B et al. Coronary flow velocity reserve and carotid intima media thickness in patients with autosomal dominant polycystic kidney disease: from impaired tubules to impaired carotid and coronary arteries. Clin J Am Soc Nephrol 2008; 3: 986-991
40. Kang DH, Nakagawa T, Feng L et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13: 2888-2897 (Pubitemid 35386908)
41. Zeier M, Fehrenbach P, Geberth S et al. Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int 1992; 42: 1259-1265
42. Menon V, Rudym D, Chandra P et al. Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6: 7-13
43. Grantham JJ, Mulamalla S, Swenson-Fields KI. Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol 2011; 7: 556-566
44. Omori H, Kawada N, Inoue K et al. Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy. Clin Exp Nephrol 2012, doi 10.1007/s10157-012-0609-3
45. Siu YP, Leung KT, Tong MK et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51-59 (Pubitemid 41828266)
46. Goicoechea M, de Vinuesa SG, Verdalles U et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010; 5: 1388-1393
47. Sweeney WE, von Vigier RO, Frost P et al. Src inhibition ameliorates polycystic kidney disease. J Am Soc Nephrol 2008; 19: 1331-1341
48. Yamaguchi T, Reif GA, Calvet JP et al. Sorafenib inhibits cAMPdependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. Am J Physiol Renal Physiol 2010; 299: F944-F951
49. Chang MY, Ong AC. Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects. Nephron Clin Pract 2012; 120: c25-c35
50. Walz G, Budde K, Mannaa M et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 830-840
51. Serra AL, Poster D, Kistler AD et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 820-829